Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$0.58 - $17.99 $3,487 - $108,173
6,013 Added 1.53%
400,006 $304,000
Q2 2022

Aug 12, 2022

BUY
$0.89 - $2.47 $12,837 - $35,627
14,424 Added 3.8%
393,993 $453,000
Q1 2022

May 13, 2022

BUY
$1.63 - $2.55 $82,450 - $128,986
50,583 Added 15.38%
379,569 $910,000
Q4 2021

Feb 11, 2022

BUY
$2.27 - $3.0 $46,487 - $61,437
20,479 Added 6.64%
328,986 $796,000
Q3 2021

Nov 12, 2021

BUY
$2.45 - $4.1 $126,042 - $210,928
51,446 Added 20.01%
308,507 $940,000
Q2 2021

Aug 13, 2021

BUY
$3.0 - $4.39 $239,859 - $350,993
79,953 Added 45.14%
257,061 $999,000
Q4 2020

Feb 12, 2021

SELL
$1.85 - $2.54 $48,068 - $65,996
-25,983 Reduced 12.79%
177,108 $382,000
Q3 2020

Nov 13, 2020

BUY
$1.85 - $2.57 $15,782 - $21,924
8,531 Added 4.38%
203,091 $410,000
Q2 2020

Aug 13, 2020

SELL
$1.59 - $2.51 $138,121 - $218,041
-86,869 Reduced 30.87%
194,560 $394,000
Q1 2020

May 14, 2020

BUY
$1.39 - $3.19 $42,912 - $98,481
30,872 Added 12.32%
281,429 $484,000
Q4 2019

Feb 13, 2020

BUY
$1.96 - $2.81 $38,517 - $55,222
19,652 Added 8.51%
250,557 $646,000
Q3 2019

Nov 12, 2019

BUY
$2.12 - $9.37 $64,799 - $286,403
30,566 Added 15.26%
230,905 $528,000
Q2 2019

Aug 14, 2019

BUY
$6.27 - $9.48 $219,757 - $332,264
35,049 Added 21.2%
200,339 $1.82 Million
Q1 2019

May 14, 2019

BUY
$7.01 - $10.24 $71,004 - $103,720
10,129 Added 6.53%
165,290 $1.25 Million
Q4 2018

Feb 13, 2019

BUY
$5.95 - $14.49 $98,716 - $240,403
16,591 Added 11.97%
155,161 $1.09 Million
Q3 2018

Nov 13, 2018

BUY
$7.51 - $14.21 $130,148 - $246,259
17,330 Added 14.29%
138,570 $1.97 Million
Q2 2018

Aug 14, 2018

BUY
$9.01 - $13.33 $502,929 - $744,067
55,819 Added 85.32%
121,240 $1.19 Million
Q1 2018

May 15, 2018

BUY
$9.38 - $12.12 $613,648 - $792,902
65,421 New
65,421 $613,000

Others Institutions Holding SYBX

About SYNLOGIC, INC.


  • Ticker SYBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,229,600
  • Market Cap $103M
  • Description
  • Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...
More about SYBX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.